Shionogi Inc patents expiration
1. Fetroja patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(10 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| New Indication (I) | Sep 25, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 2028-11-14
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
FETROJA family patents
2. Mulpleta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7601746 | SHIONOGI INC | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(11 months from now) | |
| US8889722 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jul, 2028
(4 years from now) | |
| US8530668 | SHIONOGI INC | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427402 | SHIONOGI INC | Preparation for improving solubility of poorly soluble drug |
Sep, 2031
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 2022-07-31
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET;ORAL
MULPLETA family patents
3. Ulesfia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6793931 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their applications |
Jul, 2022
(1 year, 2 months ago) | |
| US7294342 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their application |
May, 2024
(7 months from now) | |
Drugs and Companies using BENZYL ALCOHOL ingredient
Market Authorisation Date: 09 April, 2009
Treatment: Topical treatment of lice infestations
Dosage: LOTION;TOPICAL
ULESFIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic